Sofosbuvir and simeprevir for treatment of recurrent hepatitis C infection after liver transplant

Satheesh Nair, Sanjaya Satapathy, Humberto C. Gonzalez

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives: Recurrent hepatitis C is universal after liver transplant when viremia is present at the time of transplant, and this affects survival. Previous treatments with pegylated interferon and ribavirin with or without boceprevir or telaprevir have yielded modest sustained virologic response rates and frequent adverse effects. A combination of new antiviral agents has been used for recurrent hepatitis C. We aim to describe the outcomes of recurrent hepatitis C in liver transplant patients treated with simeprevir, sofosbuvir, and ribavirin. Materials and Methods: Fifty-three consecutive patients with recurrent hepatitis C genotype 1 were included. All patients had liver biopsy before enrollment if cirrhosis was not evident. Standard doses of simeprevir and sofosbuvir were used for 12 weeks. Ribavirin was adjusted based on hemoglobin levels. In 53 patients, 50 completed 12 weeks of treatment. Results: All 50 patients who completed 12 weeks of treatment achieved sustained virologic response. One patient who completed only 6 weeks also achieved sustained virologic response. Overall, the antiviral treatment was well tolerated, with no interactions with immunosuppressive drugs. Conclusions: The combination of simeprevir and sofosbuvir with or without ribavirin yields a high sustained virologic response rate of 96% in a historically difficult to treat patient population (recurrent hepatitis C genotype 1).

Original languageEnglish (US)
Pages (from-to)314-319
Number of pages6
JournalExperimental and Clinical Transplantation
Volume15
Issue number3
DOIs
StatePublished - Jun 1 2017

Fingerprint

Hepatitis C
Transplants
Ribavirin
Liver
Infection
Therapeutics
Antiviral Agents
Genotype
Viremia
Immunosuppressive Agents
Simeprevir
Sofosbuvir
Interferons
Hemoglobins
Fibrosis
Biopsy
Survival
Sustained Virologic Response
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Sofosbuvir and simeprevir for treatment of recurrent hepatitis C infection after liver transplant. / Nair, Satheesh; Satapathy, Sanjaya; Gonzalez, Humberto C.

In: Experimental and Clinical Transplantation, Vol. 15, No. 3, 01.06.2017, p. 314-319.

Research output: Contribution to journalArticle

@article{2a52c3ce2fb14fb199063e51f0219369,
title = "Sofosbuvir and simeprevir for treatment of recurrent hepatitis C infection after liver transplant",
abstract = "Objectives: Recurrent hepatitis C is universal after liver transplant when viremia is present at the time of transplant, and this affects survival. Previous treatments with pegylated interferon and ribavirin with or without boceprevir or telaprevir have yielded modest sustained virologic response rates and frequent adverse effects. A combination of new antiviral agents has been used for recurrent hepatitis C. We aim to describe the outcomes of recurrent hepatitis C in liver transplant patients treated with simeprevir, sofosbuvir, and ribavirin. Materials and Methods: Fifty-three consecutive patients with recurrent hepatitis C genotype 1 were included. All patients had liver biopsy before enrollment if cirrhosis was not evident. Standard doses of simeprevir and sofosbuvir were used for 12 weeks. Ribavirin was adjusted based on hemoglobin levels. In 53 patients, 50 completed 12 weeks of treatment. Results: All 50 patients who completed 12 weeks of treatment achieved sustained virologic response. One patient who completed only 6 weeks also achieved sustained virologic response. Overall, the antiviral treatment was well tolerated, with no interactions with immunosuppressive drugs. Conclusions: The combination of simeprevir and sofosbuvir with or without ribavirin yields a high sustained virologic response rate of 96{\%} in a historically difficult to treat patient population (recurrent hepatitis C genotype 1).",
author = "Satheesh Nair and Sanjaya Satapathy and Gonzalez, {Humberto C.}",
year = "2017",
month = "6",
day = "1",
doi = "10.6002/ect.2015.0289",
language = "English (US)",
volume = "15",
pages = "314--319",
journal = "Experimental and Clinical Transplantation",
issn = "1304-0855",
publisher = "Baskent University",
number = "3",

}

TY - JOUR

T1 - Sofosbuvir and simeprevir for treatment of recurrent hepatitis C infection after liver transplant

AU - Nair, Satheesh

AU - Satapathy, Sanjaya

AU - Gonzalez, Humberto C.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Objectives: Recurrent hepatitis C is universal after liver transplant when viremia is present at the time of transplant, and this affects survival. Previous treatments with pegylated interferon and ribavirin with or without boceprevir or telaprevir have yielded modest sustained virologic response rates and frequent adverse effects. A combination of new antiviral agents has been used for recurrent hepatitis C. We aim to describe the outcomes of recurrent hepatitis C in liver transplant patients treated with simeprevir, sofosbuvir, and ribavirin. Materials and Methods: Fifty-three consecutive patients with recurrent hepatitis C genotype 1 were included. All patients had liver biopsy before enrollment if cirrhosis was not evident. Standard doses of simeprevir and sofosbuvir were used for 12 weeks. Ribavirin was adjusted based on hemoglobin levels. In 53 patients, 50 completed 12 weeks of treatment. Results: All 50 patients who completed 12 weeks of treatment achieved sustained virologic response. One patient who completed only 6 weeks also achieved sustained virologic response. Overall, the antiviral treatment was well tolerated, with no interactions with immunosuppressive drugs. Conclusions: The combination of simeprevir and sofosbuvir with or without ribavirin yields a high sustained virologic response rate of 96% in a historically difficult to treat patient population (recurrent hepatitis C genotype 1).

AB - Objectives: Recurrent hepatitis C is universal after liver transplant when viremia is present at the time of transplant, and this affects survival. Previous treatments with pegylated interferon and ribavirin with or without boceprevir or telaprevir have yielded modest sustained virologic response rates and frequent adverse effects. A combination of new antiviral agents has been used for recurrent hepatitis C. We aim to describe the outcomes of recurrent hepatitis C in liver transplant patients treated with simeprevir, sofosbuvir, and ribavirin. Materials and Methods: Fifty-three consecutive patients with recurrent hepatitis C genotype 1 were included. All patients had liver biopsy before enrollment if cirrhosis was not evident. Standard doses of simeprevir and sofosbuvir were used for 12 weeks. Ribavirin was adjusted based on hemoglobin levels. In 53 patients, 50 completed 12 weeks of treatment. Results: All 50 patients who completed 12 weeks of treatment achieved sustained virologic response. One patient who completed only 6 weeks also achieved sustained virologic response. Overall, the antiviral treatment was well tolerated, with no interactions with immunosuppressive drugs. Conclusions: The combination of simeprevir and sofosbuvir with or without ribavirin yields a high sustained virologic response rate of 96% in a historically difficult to treat patient population (recurrent hepatitis C genotype 1).

UR - http://www.scopus.com/inward/record.url?scp=85020482589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020482589&partnerID=8YFLogxK

U2 - 10.6002/ect.2015.0289

DO - 10.6002/ect.2015.0289

M3 - Article

VL - 15

SP - 314

EP - 319

JO - Experimental and Clinical Transplantation

JF - Experimental and Clinical Transplantation

SN - 1304-0855

IS - 3

ER -